Nanobiotix S.A [NBTX] vs Denali Therapeutics [DNLI] Detailed Stock Comparison
Nanobiotix S.A
NASDAQ
Loading...
Denali Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Nanobiotix S.A wins in 7 metrics, Denali Therapeutics wins in 6 metrics, with 1 ties. Nanobiotix S.A appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Nanobiotix S.A | Denali Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -4.83 | -5.44 | Denali Therapeutics |
| Price-to-Book Ratio | N/A | 1.86 | N/A |
| Debt-to-Equity Ratio | -0.90 | 4.59 | Nanobiotix S.A |
| PEG Ratio | -2.75 | -5.22 | Denali Therapeutics |
| EV/EBITDA | -4.78 | -2.57 | Nanobiotix S.A |
| Profit Margin (TTM) | 0.00% | 0.00% | Tie |
| Operating Margin (TTM) | 271.42% | 0.00% | Nanobiotix S.A |
| EBITDA Margin (TTM) | 271.42% | N/A | N/A |
| Return on Equity | 103.70% | -35.21% | Nanobiotix S.A |
| Return on Assets (TTM) | -52.89% | -22.58% | Denali Therapeutics |
| Free Cash Flow (TTM) | $-20.40M | $-363.61M | Nanobiotix S.A |
| 1-Year Return | 41.39% | -36.44% | Nanobiotix S.A |
| Price-to-Sales Ratio (TTM) | -45.76 | N/A | N/A |
| Enterprise Value | $374.97M | $1.32B | Denali Therapeutics |
| EV/Revenue Ratio | -45.00 | N/A | N/A |
| Revenue per Share (TTM) | $0 | $0 | Denali Therapeutics |
| Earnings per Share (Diluted) | $-1.67 | $-2.67 | Nanobiotix S.A |
| Beta (Stock Volatility) | 1.50 | 1.36 | Denali Therapeutics |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Nanobiotix S.A vs Denali Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Nanobiotix S.A | 2.64% | 4.05% | 50.10% | 117.88% | 81.57% | 147.93% |
| Denali Therapeutics | -1.76% | 2.89% | -0.14% | -0.63% | -36.04% | -31.72% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Nanobiotix S.A | 41.39% | 69.12% | -59.36% | -59.36% | -59.36% | -59.36% |
| Denali Therapeutics | -36.44% | -62.66% | -53.56% | -33.66% | -33.66% | -33.66% |
Performance & Financial Health Analysis: Nanobiotix S.A vs Denali Therapeutics
| Metric | NBTX | DNLI |
|---|---|---|
| Market Information | ||
| Market Cap | $329.01M | $2.08B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 11,320 | 1,769,940 |
| 90 Day Avg. Volume | 5,990 | 1,610,353 |
| Last Close | $7.38 | $13.98 |
| 52 Week Range | $2.76 - $7.74 | $10.57 - $33.33 |
| % from 52W High | -4.65% | -58.06% |
| All-Time High | $21.55 (Dec 14, 2020) | $93.94 (Dec 21, 2020) |
| % from All-Time High | -65.75% | -85.12% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | N/A |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | 2.71% | 0.00% |
| Return on Equity (TTM) | 1.04% | -0.35% |
| Debt to Equity (MRQ) | -0.90 | 4.59 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-1.39 | $7.73 |
| Cash per Share (MRQ) | $1.05 | $5.63 |
| Operating Cash Flow (TTM) | $-22,660,391 | $-365,542,016 |
| Levered Free Cash Flow (TTM) | $-38,427,971 | $-257,539,248 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Nanobiotix S.A vs Denali Therapeutics
| Metric | NBTX | DNLI |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -4.83 | -5.44 |
| Forward P/E | -2.75 | -5.22 |
| PEG Ratio | -2.75 | -5.22 |
| Price to Sales (TTM) | -45.76 | N/A |
| Price to Book (MRQ) | N/A | 1.86 |
| Market Capitalization | ||
| Market Capitalization | $329.01M | $2.08B |
| Enterprise Value | $374.97M | $1.32B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -45.00 | N/A |
| Enterprise to EBITDA | -4.78 | -2.57 |
| Risk & Other Metrics | ||
| Beta | 1.50 | 1.36 |
| Book Value per Share (MRQ) | $-1.39 | $7.73 |
Financial Statements Comparison: Nanobiotix S.A vs Denali Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NBTX | DNLI |
|---|---|---|
| Revenue/Sales | N/A | $0 |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | N/A | $116.23M |
| Operating Income (EBIT) | N/A | $-145.58M |
| EBITDA | N/A | $-142.37M |
| Pre-Tax Income | N/A | $-132.97M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | N/A | $-132.97M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NBTX | DNLI |
|---|---|---|
| Cash & Equivalents | $49.74M | $56.95M |
| Total Current Assets | $61.47M | $878.64M |
| Total Current Liabilities | $58.94M | $91.88M |
| Long-Term Debt | $45.98M | $40.05M |
| Total Shareholders Equity | $-65.70M | $1.12B |
| Retained Earnings | $-68.13M | $-1.67B |
| Property, Plant & Equipment | $2.49M | $129.93M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NBTX | DNLI |
|---|---|---|
| Operating Cash Flow | N/A | $-92.50M |
| Capital Expenditures | N/A | $-5.08M |
| Free Cash Flow | N/A | $-136.55M |
| Debt Repayment | N/A | $-4.36M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NBTX | DNLI |
|---|---|---|
| Shares Short | 6,060 | 12.68M |
| Short Ratio | 1.56 | 8.55 |
| Short % of Float | 0.00% | 0.10% |
| Average Daily Volume (10 Day) | 11,320 | 1,769,940 |
| Average Daily Volume (90 Day) | 5,990 | 1,610,353 |
| Shares Outstanding | 47.40M | 144.22M |
| Float Shares | 24.67M | 130.75M |
| % Held by Insiders | 0.00% | 0.10% |
| % Held by Institutions | 0.12% | 0.94% |
Dividend Analysis & Yield Comparison: Nanobiotix S.A vs Denali Therapeutics
| Metric | NBTX | DNLI |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |